Tag Archives: Bioscience

Can Cannabinoids Help Keep the Aging Body Balanced?

As our bodies age, the mechanisms that keep our systems humming, such as immune regulation, metabolism, and neural repair, gradually erode. That loss of homeostasis is the culprit behind many age-related disorders, from cognitive decline to metabolic dysfunction. Scientists are beginning to explore whether cannabis or its constituent cannabinoids might help support the body’s natural ability to maintain equilibrium as it ages.

The Journal of Cannabis Research is an international, fully open-access, peer-reviewed journal that welcomes submissions on all aspects of cannabis research. Their 2025 systematic review, “The Impact of Cannabis Use on Aging and Longevity: A Systematic Review of Research Insights,” pooled data from preclinical and human studies. The authors concluded that cannabinoids show promise in modulating aging processes, although human evidence remains limited. The review provides a solid foundation, but recent mechanistic and methodological work adds important nuance and depth to the understanding.

 

Rewiring the Aging Brain

One compelling line of evidence comes from a study showing that continuous administration of low-dose THC (3 mg/kg/day) over 28 days in 18-month-old mice counteracted age-related decline in dendritic spine dynamics in cortical neurons. The treated mice showed reduced spine loss and increased spine survival, essentially re-establishing neural stability similar to that of young mice. The researchers observed that the probability of spine survival in THC-treated old mice reached levels comparable to those in 3-month-old controls (Komorowska-Müller et al., Nature).

This supports the idea that cannabinoids may actively restore structural stability in neural circuits rather than merely slowing decay. Earlier work by Bilkei-Gorzo et al. (2017) demonstrated that chronic low-dose THC reversed age-related cognitive decline in 12- and 18-month-old mice. Their treated mice displayed increased hippocampal spine density, stronger expression of synaptic marker proteins, and gene transcription changes that made them more similar to younger mice.

 

A Two-Way Switch for Aging Cells

Recent studies highlight the nuanced, tissue-specific effects of cannabinoids. A 2024 study revealed that long-term low-dose THC produces a bidirectional effect. In the brain, THC transiently enhances mTOR signaling and increases the levels of amino acids and energy metabolites, thereby promoting synaptic protein synthesis and neural repair. At the same time, in peripheral tissues such as adipose, THC reduces mTOR activity and suppresses metabolic overactivity, effects similar to those seen with caloric restriction or exercise interventions (Bilkei-Gorzo et al., ACS Pharmacology & Translational Science).

This dual effect suggests that THC may act as a metabolic switch, enhancing repair in the central nervous system while balancing peripheral metabolism. Such tissue-specific modulation offers a promising model for a homeostasis-based therapeutic approach.

 

How Men and Women Respond Differently

Emerging research is exploring other cannabinoids as well. A 2025 study on cannabinol (CBN) found that it improved spatial memory and learning in aging mice, particularly in females. These findings suggest that the antiaging potential of cannabis is not limited to THC or CBD, and that sex differences may influence response.

It is worth noting that both human and animal studies have observed sex-specific pharmacokinetic differences in cannabis metabolism and sensitivity, even when equivalent doses are administered. This indicates that men and women may experience distinct benefits or side effects from the same cannabis formulations.

 

Can Too Much Cannabis Age You Faster?

While the potential benefits are compelling, some evidence suggests that chronic cannabis use may accelerate specific aging markers in humans. A longitudinal study titled “Lifetime Marijuana Use and Epigenetic Age Acceleration: A 17-year Study” found that heavier lifetime marijuana users exhibited significantly greater epigenetic aging, measured by DNAmGrimAge clocks, even after adjusting for tobacco use and other confounders (PMC).

Cannabis smoking has also been linked to higher levels of IL-1β, a proinflammatory cytokine, along with elevated methylation clock measures, though some effects appear reversible with cessation (PMC review).

Reviews of epigenetic effects suggest that cannabinoids can alter methylation patterns across genes associated with neurotransmission, immune signaling, and cellular repair (ScienceDirect). A recent molecular epidemiology study also reported dozens of DNA methylation sites in middle-aged adults associated with both cumulative and recent marijuana use, reinforcing cannabis’s potential influence on aging trajectories (Nature).

These findings point to the complexity of cannabis’s effects on homeostasis. Factors such as dose, age of onset, duration of use, cannabinoid type, and mode of consumption likely determine whether cannabis supports or undermines healthy aging.

 

Hope, Caution, and the Path Forward

Cannabinoids offer intriguing possibilities for mitigating age-related decline, from restoring neural circuit stability to rebalancing metabolic signaling and possibly influencing molecular aging pathways. Yet the evidence remains inconclusive. In preclinical studies, low-dose THC consistently demonstrates beneficial effects, and emerging research on CBN suggests additional promise. However, human data are still limited, and the potential for epigenetic acceleration calls for careful attention.

Currently, cannabinoids may represent one tool among many for supporting homeostasis in aging, provided they are used with close attention to dosing, timing, compound specificity, and tailored to the individual’s needs. As more human trials and longitudinal studies emerge, we may gain a better understanding of how these compounds can help the aging body maintain balance and resilience while minimizing risk.

 

 

Deibel Bioscience Rebrands, Achieves ISO 17025 Accreditation

By Cannabis Industry Journal Staff
No Comments

On June 19, Charles Deibel, president and CEO of Deibel Bioscience, announced two important changes to his cannabis testing laboratory: First, they changed their name from Deibel Laboratories to Deibel Bioscience. Secondly, they achieved ISO/IEC 17025:2017 accreditation.

Deibel Labs is an internationally recognized corporation of 15 testing labs in North America that’s been around for about 50 years, serving the food, beverage and personal care industries. Starting in 2018, Deibel has ventured into the cannabis and hemp markets, and recently rebranded these labs as “Deibel Bioscience.” Currently, Deibel Bioscience operates in California and Illinois, with plans underway to open labs in Florida and Pennsylvania.

Charles Deibel, President & CEO of Deibel Bioscience

Deibel’s brand is very well known in the food testing industry and has recently become a prominent voice and industry advocate in the cannabis testing community. Charles Deibel’s father, Dr. Robert Deibel, was a pioneer of the Hazard Analysis and Critical Control Point (HACCP) system. Charles Deibel has a long career in the laboratory testing space and even worked with the Department of Justice to help shape the legal case against Peanut Corporation of America and testified as an expert witness during the trial.

With respect to their accreditation, Deibel Bioscience of California (Santa Cruz) achieved it through the American Association for Laboratory Accreditation (A2LA). The lab’s scope currently holds seven chemical and microbiological test methods as well as their sampling method, with plans to expand their scope to include four more chemical testing methods in the next month.

“At our level of testing services, any lab should be able to offer accurate testing, at a fair price and a reasonable turn-around time,” says Deibel. “These three qualities are no longer defining features; rather it is our high level of service and exceptional Technical Services acumen that set us apart.”

According to Deibel, their company is drawing on decades of experience in other testing industries to provide a high caliber of technical expertise. “We are a family owned and operated corporation and are not constrained by quarterly investor demands. Our size offers economics of scale that is reflected in our service and pricing.”